AU1249501A - Nucleic acid encoding human abca transporter 2 (abca2) and methods of use thereof - Google Patents
Nucleic acid encoding human abca transporter 2 (abca2) and methods of use thereof Download PDFInfo
- Publication number
- AU1249501A AU1249501A AU12495/01A AU1249501A AU1249501A AU 1249501 A AU1249501 A AU 1249501A AU 12495/01 A AU12495/01 A AU 12495/01A AU 1249501 A AU1249501 A AU 1249501A AU 1249501 A AU1249501 A AU 1249501A
- Authority
- AU
- Australia
- Prior art keywords
- abca2
- sequence
- nucleic acid
- human
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims description 93
- 102000039446 nucleic acids Human genes 0.000 title claims description 84
- 108020004707 nucleic acids Proteins 0.000 title claims description 84
- 238000000034 method Methods 0.000 title claims description 53
- 102000018723 Subfamily A ATP Binding Cassette Transporter Human genes 0.000 title 1
- 108010091956 Subfamily A ATP Binding Cassette Transporter Proteins 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims description 153
- 102000004169 proteins and genes Human genes 0.000 claims description 107
- 210000004027 cell Anatomy 0.000 claims description 84
- 108020004414 DNA Proteins 0.000 claims description 39
- 101000801645 Homo sapiens ATP-binding cassette sub-family A member 2 Proteins 0.000 claims description 35
- 239000002299 complementary DNA Substances 0.000 claims description 33
- 230000014509 gene expression Effects 0.000 claims description 32
- 108010078791 Carrier Proteins Proteins 0.000 claims description 31
- 102000056779 human ABCA2 Human genes 0.000 claims description 30
- 230000027455 binding Effects 0.000 claims description 27
- 241001465754 Metazoa Species 0.000 claims description 22
- 230000035772 mutation Effects 0.000 claims description 22
- 101150033922 ABCA2 gene Proteins 0.000 claims description 21
- 239000002773 nucleotide Substances 0.000 claims description 21
- 125000003729 nucleotide group Chemical group 0.000 claims description 20
- 150000001413 amino acids Chemical class 0.000 claims description 17
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 16
- 239000002246 antineoplastic agent Substances 0.000 claims description 13
- 230000001105 regulatory effect Effects 0.000 claims description 11
- 238000012216 screening Methods 0.000 claims description 11
- 239000013598 vector Substances 0.000 claims description 11
- 102000053602 DNA Human genes 0.000 claims description 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 10
- 230000000692 anti-sense effect Effects 0.000 claims description 9
- 108020004999 messenger RNA Proteins 0.000 claims description 9
- 108050006654 Lipocalin Proteins 0.000 claims description 8
- 230000003321 amplification Effects 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 8
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 8
- 239000013612 plasmid Substances 0.000 claims description 8
- 230000002441 reversible effect Effects 0.000 claims description 8
- 102000019298 Lipocalin Human genes 0.000 claims description 7
- 238000011830 transgenic mouse model Methods 0.000 claims description 7
- 101100161486 Mus musculus Abca2 gene Proteins 0.000 claims description 6
- 230000001413 cellular effect Effects 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 230000035945 sensitivity Effects 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 230000013595 glycosylation Effects 0.000 claims description 5
- 238000006206 glycosylation reaction Methods 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 4
- 230000006801 homologous recombination Effects 0.000 claims description 4
- 238000002744 homologous recombination Methods 0.000 claims description 4
- 102100033618 ATP-binding cassette sub-family A member 2 Human genes 0.000 claims description 3
- 241000238631 Hexapoda Species 0.000 claims description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims description 3
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 3
- 230000002538 fungal effect Effects 0.000 claims description 3
- 230000026731 phosphorylation Effects 0.000 claims description 3
- 238000006366 phosphorylation reaction Methods 0.000 claims description 3
- 239000003155 DNA primer Substances 0.000 claims description 2
- 238000000520 microinjection Methods 0.000 claims description 2
- 239000013641 positive control Substances 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 230000001177 retroviral effect Effects 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- 102000040811 transporter activity Human genes 0.000 claims description 2
- 108091092194 transporter activity Proteins 0.000 claims description 2
- 108700024394 Exon Proteins 0.000 claims 3
- 230000005764 inhibitory process Effects 0.000 claims 3
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108091092195 Intron Proteins 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000006491 negative regulation of transport Effects 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 106
- 239000000523 sample Substances 0.000 description 28
- 239000013615 primer Substances 0.000 description 25
- 230000032258 transport Effects 0.000 description 24
- 239000012634 fragment Substances 0.000 description 23
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 22
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 description 22
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 description 21
- 108090000765 processed proteins & peptides Proteins 0.000 description 21
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 20
- 210000004556 brain Anatomy 0.000 description 20
- 238000003752 polymerase chain reaction Methods 0.000 description 20
- 102100033616 Phospholipid-transporting ATPase ABCA1 Human genes 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 16
- 238000009396 hybridization Methods 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 230000001605 fetal effect Effects 0.000 description 12
- 238000002512 chemotherapy Methods 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 101150092476 ABCA1 gene Proteins 0.000 description 10
- 108700005241 ATP Binding Cassette Transporter 1 Proteins 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 10
- 238000013459 approach Methods 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 230000002209 hydrophobic effect Effects 0.000 description 10
- 230000009870 specific binding Effects 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 230000002068 genetic effect Effects 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 101000801640 Homo sapiens Phospholipid-transporting ATPase ABCA3 Proteins 0.000 description 8
- 102100033623 Phospholipid-transporting ATPase ABCA3 Human genes 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 210000000170 cell membrane Anatomy 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 230000009261 transgenic effect Effects 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 230000004075 alteration Effects 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 7
- 229960001842 estramustine Drugs 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 6
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000011813 knockout mouse model Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 150000003431 steroids Chemical class 0.000 description 6
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 5
- 101000990566 Homo sapiens HEAT repeat-containing protein 6 Proteins 0.000 description 5
- 101000801684 Homo sapiens Phospholipid-transporting ATPase ABCA1 Proteins 0.000 description 5
- 208000027073 Stargardt disease Diseases 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000013507 mapping Methods 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 108700028369 Alleles Proteins 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 208000001163 Tangier disease Diseases 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 230000001594 aberrant effect Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 208000002780 macular degeneration Diseases 0.000 description 4
- 108091008695 photoreceptors Proteins 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 108020005345 3' Untranslated Regions Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 101000677891 Homo sapiens Iron-sulfur clusters transporter ABCB7, mitochondrial Proteins 0.000 description 3
- 102100021504 Iron-sulfur clusters transporter ABCB7, mitochondrial Human genes 0.000 description 3
- 230000004988 N-glycosylation Effects 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 101710205202 Phospholipid-transporting ATPase ABCA1 Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 208000006756 X-linked sideroblastic anemia Diseases 0.000 description 3
- 208000022440 X-linked sideroblastic anemia 1 Diseases 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000013599 cloning vector Substances 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 230000000858 peroxisomal effect Effects 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 201000007245 sideroblastic anemia 1 Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 108020003589 5' Untranslated Regions Proteins 0.000 description 2
- 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 2
- 108700036213 ATP-binding cassette subfamily A member 2 Proteins 0.000 description 2
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- 206010053684 Cerebrohepatorenal syndrome Diseases 0.000 description 2
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 2
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101100161485 Homo sapiens ABCA2 gene Proteins 0.000 description 2
- 108091006975 Iron transporters Proteins 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000010796 X-linked adrenoleukodystrophy Diseases 0.000 description 2
- 201000004525 Zellweger Syndrome Diseases 0.000 description 2
- 208000036813 Zellweger spectrum disease Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009056 active transport Effects 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 230000002927 anti-mitotic effect Effects 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 230000004656 cell transport Effects 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 210000000877 corpus callosum Anatomy 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
- 229960002963 ganciclovir Drugs 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000001767 medulla oblongata Anatomy 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 210000000880 retinal rod photoreceptor cell Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000001103 thalamus Anatomy 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000002676 xenobiotic agent Substances 0.000 description 2
- IPVFGAYTKQKGBM-BYPJNBLXSA-N 1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound F[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 IPVFGAYTKQKGBM-BYPJNBLXSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101150039555 ABCA4 gene Proteins 0.000 description 1
- 208000036443 AIPL1-related retinopathy Diseases 0.000 description 1
- 108050008780 ATP-binding cassette sub-family D member 1 Proteins 0.000 description 1
- 102100020973 ATP-binding cassette sub-family D member 3 Human genes 0.000 description 1
- 101710152924 ATP-binding cassette sub-family D member 3 Proteins 0.000 description 1
- 102100022654 ATP-binding cassette sub-family F member 2 Human genes 0.000 description 1
- 101710205102 ATP-binding cassette transporter abc1 Proteins 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 101100220239 Caenorhabditis elegans ced-7 gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000005403 Casein Kinases Human genes 0.000 description 1
- 108010031425 Casein Kinases Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 102100040492 Complement component C8 gamma chain Human genes 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102100023419 Cystic fibrosis transmembrane conductance regulator Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 101100364969 Dictyostelium discoideum scai gene Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108091060211 Expressed sequence tag Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010081520 Glycodelin Proteins 0.000 description 1
- 102000004240 Glycodelin Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 101000823289 Homo sapiens ATP-binding cassette sub-family F member 2 Proteins 0.000 description 1
- 101000749897 Homo sapiens Complement component C8 gamma chain Proteins 0.000 description 1
- 101000767151 Homo sapiens General vesicular transport factor p115 Proteins 0.000 description 1
- 101000577953 Homo sapiens Mitochondrial potassium channel ATP-binding subunit Proteins 0.000 description 1
- 101001099372 Homo sapiens Peroxisome biogenesis factor 1 Proteins 0.000 description 1
- 101001093919 Homo sapiens SEC14-like protein 2 Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010057281 Lipocalin 1 Proteins 0.000 description 1
- 102000013519 Lipocalin-2 Human genes 0.000 description 1
- 108010051335 Lipocalin-2 Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 201000007114 MHC class I deficiency Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 108090001099 Multi drug resistance-associated proteins Proteins 0.000 description 1
- 102000004855 Multi drug resistance-associated proteins Human genes 0.000 description 1
- 102100021339 Multidrug resistance-associated protein 1 Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100364971 Mus musculus Scai gene Proteins 0.000 description 1
- 101100384865 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cot-1 gene Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 102100038881 Peroxisome biogenesis factor 1 Human genes 0.000 description 1
- 102000048176 Prostaglandin-D synthases Human genes 0.000 description 1
- 108030003866 Prostaglandin-D synthases Proteins 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 101001010097 Shigella phage SfV Bactoprenol-linked glucose translocase Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108091027568 Single-stranded nucleotide Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108010091105 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 102000018075 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- 101150090313 abc1 gene Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000001159 caudate nucleus Anatomy 0.000 description 1
- 101150043721 ced-7 gene Proteins 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 201000006754 cone-rod dystrophy Diseases 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000009402 cross-breeding Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 210000002458 fetal heart Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000012248 genetic selection Methods 0.000 description 1
- 210000002980 germ line cell Anatomy 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000005099 mouse brain capillary cell Anatomy 0.000 description 1
- 108010066052 multidrug resistance-associated protein 1 Proteins 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- -1 nucleotide triphosphates Chemical class 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000000869 occipital lobe Anatomy 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000002891 organic anions Chemical class 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000001152 parietal lobe Anatomy 0.000 description 1
- 108010082406 peptide permease Proteins 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 210000002975 pon Anatomy 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 210000002637 putamen Anatomy 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 210000004358 rod cell outer segment Anatomy 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000013606 secretion vector Substances 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 208000031162 sideroblastic anemia Diseases 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 108010055094 transporter associated with antigen processing (TAP) Proteins 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000002034 xenobiotic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Description
WO01/21798 PCTIUS00/40789 Nucleic Acid Encoding Human ABCA Transporter 2 (ABCA2) and Methods of Use Thereof By Kenneth D. Tew Bojana Vulevic 5 Zhijian Chen Pursuant to 35 U.S.C. 9202(c) it is acknowledged that the U.S. Government has certain rights in the invention described herein, which was made in part with 10 funds from the National Institutes of Health, Grant Number, 5 R35 CA53893-07. FIELD OF THE INVENTION The present invention relates to the fields of 15 medicine and molecular biology. More specifically, the invention provides nucleic acid molecules and proteins encoded thereby which are involved in the regulated transport of biological and pharmacological molecules across cell membranes. 20 BACKGROUND OF THE INVENTION Several publications are referenced in this application in parentheses in order to more fully describe the state of the art to which this invention 25 pertains. The disclosure of each of these publications is incorporated by reference herein. The ABC transporters are members of the family of cellular membrane proteins responsible for unidirectional movement of many different substrates across biological 30 membranes in prokaryotes and eukaryotes (Higgins, 1992). These ABC transporters share structural similarity with most having one or two highly conserved ATP binding cassette (ABC) regions and one or two highly hydrophobic domains often with six transmembrane segments (Luciani et 35 al, 1994). Commonly, family members have a two plus two structure and are regarded as full-size transporters, as opposed to half transporters which contain one ATP WO01/21798 PCT/US00/40789 binding cassette and one hydrophobic domain. ABC transporters localize to plasma membranes (P glycoprotein, MRPs) or to the internal membranes of different organelles (ALD, TAP, ABC7, M-ABC1). 5 Many ABC transporters play important roles in the cellular efflux of endogenous or xenobiotic substrates, and their biological dysfunction has been implicated in a number of clinical disorders. For example, impaired function of the cAMP activated CFTR chloride channel 10 appears to be the basic defect in epithelial and non epithelial cells derived from cystic fibrosis patients (Kunzelmann, 1999). Mutations in peroxisomal membrane half-transporters, ALDP and PMP70 are associated with abnormal peroxisomal beta-oxidation of saturated, very 15 long chain fatty acids giving rise to neurodegenerative disorders such as X-linked adrenoleukodistrophy and Zellweger syndrome (Smith et al., 1999; Collins and Could, 1999). Aberrant expression of half-transporters, such as TAP-transporters (de la Salle et al., 1994; Cucca 20 et al., 1994) has been linked to diseases like bare lymphocyte syndrome I and insulin-dependent diabetes mellitus. These proteins localize to endoplasmic reticulum and are involved in antigen processing. The mitochondrial half-transporter, ABC7 has been associated 25 with a range of hereditary diseases in humans (Savary et al., 1997; Shimada et al., 1998; Csere et al., 1998; Allikmets et al., 1999). The mutations in this iron transporter are responsible for X-linked sideroblastic anemia and ataxia (XLSA/A). More recently, ABCR or ABCA4, 30 the rod photoreceptor ABC transporter has been implicated in a whole spectrum of vision disorders (Evans and Bhattacharya, 1998; Rozet et al., 1998; Shroyer et al., 1999; Maugeri et al., 1999; Lewis et al., 1999). Mutations in the ABCR gene interfere with transport 35 functions which can lead to conditions associated with 2 WU 1/21798 PCTIUS00/40789 Stargard Disease, AMD (age-related macular degeneration), Fundus Flavimaculatus, Cone-Rod Dystrophy and Retinitis Pigmentosa. Kinetic analysis of the ATPase activity of ABCR (Sun et al., 1999) and characterization of abcr 5 knockout mice (Weng et al., 1999) showed that ABCR probably functions as an outwardly directed flippase for N-retinylidene-phosphatidylethanolamine, protecting the retinal pigment epithelium from toxic adducts of photobleaching. ABC1, a mammalian homologue of the C. 10 elegans ced-7 gene, has been shown to be required for phagocytosis of both necrotic and apoptotic cells (Luciani and Chimini, 1996; Mounaylt et al., 1998;) and is involved in macrophage interleukin-1 secretion (Hamon et al., 1997). This protein has also been found to 15 function as a cholesterol pump and some mutations in the ABC1 gene are causative for Tangier disease and familial high-density cholesterol deficiency with high predisposition for atherosclerosis (Langmann et al., 1999; Brooks-Wilson et al., 1999; Bodzioch et al., 1999; 20 Rust et al., 1999.) The mechanism(s) underlying these apparently loosely related functions has yet to be addressed. Extending the drug resistance paradigm, research from our laboratory on the ABCA2 transporter revealed 25 that amplification of the ABCA2 gene was linked to resistance to estramustine (Laing et al., 1998). Both gene copy number and mRNA levels of this transporter were increased in the resistant cell line. In addition, antisense treatment directed toward ABCA2 mRNA sensitized 30 the resistant cells to estramustine. Together, these results suggested that ABCA2 is causally involved in estramustine resistance and implied a possible role for ABCA2 in steroid transport. 35 3 WO01/21798 PCT/US00/40789 SUMMARY OF THE INVENTION This invention provides novel, biological molecules useful for identification, detection, and/or molecular characterization of components involved in the 5 transport of molecules across cell membranes. According to one aspect of the invention, an isolated nucleic acid molecule is provided which includes a sequence encoding a full length human ABCA2 protein transporter of a size about 2436 amino acids in length. The encoded protein, 10 referred to herein as human ABCA2 comprises a multi-domain structure including a tandem repeat of nucleotide binding folds appended to a hydrophobic domain that contains several potential membrane spanning helices. Conserved Walker A and B ATP binding sites are 15 present in each of the nucleotide binding folds. In a preferred embodiment of the invention, an isolated nucleic acid molecule is provided that includes a cDNA encoding a human ABCA2 protein. In a particularly preferred embodiment, the human ABCA2 protein has an 20 amino acid sequence the same as Sequence I.D. No. 2. An exemplary human ABCA2 nucleic acid molecule of the invention comprises Sequence I.D. No. 1. According to another aspect of the present invention, an isolated nucleic acid molecule is provided, 25 which has a sequence selected from the group consisting of: (1) Sequence I.D. No. 1; (2) a sequence specifically hybridizing with preselected portions or all of the complementary strand of Sequence I.D. No. 1 comprising nucleic acids encoding amino acids 1-20, 1-35, 1-40, 1-60 30 and 1-150 of Sequence ID No. 2; (3) a sequence encoding preselected portions of Sequence I.D. No. 1 within nucleotides 1-200. Such partial sequences are useful as probes to identify and isolate homologues of the human ABCA2 genes 35 of the invention. Additionally, isolated nucleic acid 4 WO01/21798 PCTIUS00/40789 sequences encoding natural allelic variants of the nucleic acids of Sequence I.D. No. 1 are also contemplated to be within the scope of the present invention. The term natural allelic variants will be 5 defined hereinbelow. According to another aspect of the present invention, antibodies immunologically specific for the human ABCA2 proteins described hereinabove are provided. In yet another aspect of the invention, host cells 10 comprising the human ABCA2 encoding nucleic acid of the invention are provided. Such host cells include but are not limited to bacterial cells, fungal cells, insect cells, mammalian cells, and plant cells. Host cells overexpressing the human ABCA2 encoding nucleic acids of 15 the invention provide valuable research tools for assessing transport of chemotherapeutic agents out of cells. Human ABCA2 expressing cells also comprise a biological system useful in methods for identifying inhibitors of the ABCA2 transporters. 20 Another embodiment of the present invention encompasses methods for screening cells expressing the human ABCA2 encoding nucleic acids for chemotherapy resistance. Such methods will provide the clinician with data which correlates expression of a particular human 25 ABCA2 gene with a particular chemotherapy resistant phenotype. Diagnostic methods are also contemplated in the present invention. Accordingly, suitable oligonucleotide probes are provided which hybridize to the nucleic acids 30 of the invention. Such probes may be used to advantage in screening biopsy samples for the expression of mutated ABCA2 genes. The methods of the invention may be applied to kits. An exemplary kit of the invention comprises ABCA2 gene 35 specific oligonucleotide probes and/or primers, ABCA2 5 WO01/21798 PCT/US00/40789 encoding DNA molecules for use as a positive control, buffers, and an instruction sheet. A kit for practicing the cell line screening method includes frozen cells comprising the human ABCA2 encoding nucleic acid of the 5 invention, suitable culture media, buffers and an instruction sheet. In a further aspect of the invention, transgenic knockout mice are disclosed. Mice will be generated in which the ABCA2 gene has been knocked out. Such mice 10 will provide a valuable biological system for assessing resistance to chemotherapy in an in vivo tumor model. Various terms relating to the biological molecules of the present invention are used hereinabove and also throughout the specification and claims. The terms 15 "percent similarity" and "percent identity (identical)" are used as set forth in the UW GCG Sequence Analysis program (Devereux et al. NAR 12:387-397 (1984)). With reference to nucleic acids of the invention, the term "isolated nucleic acid" is sometimes used. This 20 term, when applied to DNA, refers to a DNA molecule that is separated from sequences with which it is immediately contiguous (in the 5' and 3' directions) in the naturally occurring genome of the organism from which it originates. For example, the "isolated nucleic acid" may 25 comprise a DNA or cDNA molecule inserted into a vector, such as a plasmid or virus vector, or integrated into the genomic DNA of a prokaryote or eukaryote. With respect to RNA molecules of the invention, the term "isolated nucleic acid" primarily refers to an RNA 30 molecule encoded by an isolated DNA molecule as defined above. Alternatively, the term may refer to an RNA molecule that has been sufficiently separated from RNA molecules with which it would be associated in its natural state (i.e., in cells or tissues), such that it 35 exists in a "substantially pure" form (the term 6 WO01/21798 PCT/US00/40789 "substantially pure" is defined below). With respect to protein, the term "isolated protein" or "isolated and purified protein" is sometimes used herein. This term refers primarily to a protein produced 5 by expression of an isolated nucleic acid molecule of the invention. Alternatively, this term may refer to a protein which has been sufficiently separated from other proteins with which it would naturally be associated, so as to exist in "substantially pure" form. 10 The term "substantially pure" refers to a preparation comprising at least 50-60% by weight the compound of interest (e.g., nucleic acid, oligonucleotide, protein, etc.). More preferably, the preparation comprises at least 75% by weight, and most 15 preferably 90-99% by weight, the compound of interest. Purity is measured by methods appropriate for the compound of interest (e.g. chromatographic methods, agarose or polyacrylamide gel electrophoresis, HPLC analysis, and the like). 20 With respect to antibodies of the invention, the term "immunologically specific" refers to antibodies that bind to one or more epitopes of a protein of interest (e.g., human ABCA2), but which do not substantially recognize and bind other molecules in a sample containing 25 a mixed population of antigenic biological molecules. With respect to nucleic acids and oligonucleotides, the term "specifically hybridizing" refers to the association between two single-stranded nucleotide molecules of sufficiently complementary sequence to 30 permit such hybridization under pre-determined conditions generally used in the art (sometimes termed "substantially complementary"). When used in reference to a double stranded nucleic acid, this term is intended to signify that the double stranded nucleic acid has been 35 subjected to denaturing conditions, as is well known to 7 WU U01/21798 PCT/US00/40789 those of skill in the art. In particular, the term refers to hybridization of an oligonucleotide with a substantially complementary sequence contained within a single-stranded DNA or RNA molecule of the invention, to 5 the substantial exclusion of hybridization of the oligonucleotide with single-stranded nucleic acids of non-complementary sequence. One common formula for calculating the stringency conditions required to achieve hybridization between 10 nucleic acid molecules of a specified sequence homology (Sambrook et al., 1989): Tm = 81.50C + 16.6Log [Na+] + 0.41(% G+C) - 0.63 (% formamide) 600/#bp in duplex 15 As an illustration of the above formula, using [Na+] = [0.368] and 50% formamide, with GC content of 42% and an average probe size of 200 bases, the Tm is 57oC. The Tm of a DNA duplex decreases by 1 - 1.5 0 C with every 1% 20 decrease in homology. Thus, targets with greater than about 75% sequence identity would be observed using a hybridization temperature of 42 0 C. Such sequences would be considered substantially homologous to the nucleic acid sequences of the invention. 25 The nucleic acids, proteins, antibodies, cell lines, methods, and kits of the present invention may be used to advantage to identify targets for the development of novel agents which inhibit the aberrant transport of biological and pharmacological agents into and out of 30 cells. The transgenic mice of the invention may be used in an in vivo model for chemotherapy resistance. The human ABCA2 molecules, methods and kits described above may also be used as research tools and will facilitate the elucidation of the mechanism by which 35 cellular transport may be augmented or inhibited. 8 WO01/21798 PCT/US00/40789 BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1. Diagram showing overlapping clones used to define the full-length cDNA of ABCA2. The white boxes represent the untranslated regions. A 1.75 kb fragment 5 was originally PCR amplified. Clones designated as 2 represent clones isolated from oligo(dT) and random primed human fetal brain phage library. Other clones were isolated using RACE PCR with human brain Marathon cDNA. The only exception is clone AB028985, which stands 10 for GenBank accession number of brain KIAA1062 protein. The most 5' clones, 65 and 119 contain the ATG start codon designated at position 1 representing a previously described sequence of a brain cDNA (GenBank Accession Number AB028985). 15 Figs. 2A, 2B, 2C and 2D. Primary structure analysis of human ABCA2. Fig. 2A: Amino acid sequence predicted from the full length ABCA2 cDNA. The 12 predicted transmembrane-spanning segments are indicated with a 20 heavy bar below the sequence and the corresponding numerals below. The 21 predicted N-glycosylation sites on the extracellular surface are indicated by "*" Residues comprising the extended ATP-binding cassettes are underlined and indicated by "ATP binding cassette". 25 The highly hydrophobic domain is underlined and labeled as "HHD". The nucleotide sequence was deposited in GenBank under accession number AF 178941. Fig. 2B: Kyle Doolittle hydrophobicity analysis of ABCA2 protein. The shaded areas above line are hydrophobic and those below 30 are hydrophilic. Analysis was performed in GCG software. Fig. 2C: Schematic showing the predicted topology of ABCA2 in the membrane. The extracellular surface is on the top and the cytoplasmic on the bottom of the figure. The stylized rods on the cytoplasmic loop show 35 N-glycosylation sites. Fig. 2D: Dot-matrix plot of human 9 WO01/21798 PCT/US00/40789 ABCA2 against itself, with PAM 250 matrix and a window of 8 residues, shows little sequence similarity outside the nucleotide folds. 5 Fig. 3. Multialignment of the amino acid sequences of the extended nucleotide binding cassettes from the group of ABCl-similar proteins. Clustal-W analysis was performed in Mac Vector software. Shading highlights the conserved residues. Underlined are ATP binding cassette 10 sequence motifs: WA stands for Walker motif A; WB stands for Walker motif B and ATS corresponds to active transport signature. The reported sequences were extracted from the GenBank database, under the following Accession numbers: ABCA4 (human): NM_000341; 15 ABCA3(human): NM_001089; ABCA2(human) AF178941; ABCAl(human): AAF86276; abca2 (mouse): CAA53531. Fig. 4. Multiple Northern analysis blot. Blot containing 1 pg of polyA+ RNA from each tissue hybridized 20 with an 870 bp ABCA2 probe (top panel) or with a 1-actin probe (bottom panel). Fig. 5. Tissue distribution of the human ABCA2. A human MTE Array (Clontech, Palo Alto, CA) was probed with 25 a 840 bp biotin labeled fragment of ABCA2. Hybridization, detection and quantitation of signal are described further hereinbelow. Al-10: whole brain, cerebral cortex, frontal lobe, parietal lobe, occipital lobe, temporal lobe, cerebral cortex, pons, 30 cerebellum-left, cerebellum-right; Bl-10: corpus callosum, amygdala, caudate nucleus, hippocampus, medulla oblongata, putamen, substantia nigra, accumbens nucleus, thalamus, pituitary gland; Cl-10: spinal cord, heart, aorta, atrium-left, atrium-right, ventricle-left, 35 ventricle-right, interventricular septum, apex of the 10 WO01/21798 PCT/US00/40789 heart, esophagus; DI-10: stomach, duodenum, jejunum, ileum, ilocecum, appendix, colon-ascending, colon-transverse, colon-descending, rectum; El-10: kidney, skeletal muscle, spleen, thymus, peripheral blood 5 leukocyte, lymph node, bone marrow, trachea, lung, placenta; Fl-10: bladder, uterus, prostate, testis, ovary, liver, pancreas, adrenal gland, thyroid gland, salivary gland; Gl-10: mammary gland, leukemia HL-60, HeLa S3, leukemia K-562, leukemia MOLT-4, Burkitt's 10 lymphoma-Raji, colorectal adeno-carcinoma-SW480, lung carcinoma-A549, fetal brain; Hl-10: fetal heart, fetal kidney, fetal liver, fetal spleen, fetal thymus, fetal lung, yeast total RNA, yeast tRNA, E.coli rRNA, E. coli DNA; Il-10:Poly r(A), human Cot_1 DNA, human DNA 100 ng, 15 human DNA 500 ng. Figs. 6A and 6B. Sequence ID No. 1. Fig. 7. Sequence ID No. 2. 20 DETAILED DESCRIPTION OF THE INVENTION An isolated human ABCA2 encoding nucleic acid, the protein encoded thereby and antibodies immunologically specific for the ABCA2 protein are provided in the 25 present invention. Based on the degree of amino acid identity ABCA2 can be regarded as an ortholog of mouse ABCA2 (Luciani et al., 1994). This protein is closely related to members of ABCl-subfamily of transporters, ABCA1, ABCA4 and ABCA3 and more distantly related to MDR1 30 (Chen et al., 1986), MRPl(Riordan et al., 1989) and CFTR (Zielenski et al., 1991). The topology of ABCA2 is reminiscent of that observed in ABCA4 (Illing et al., 1997; Azarian and Travis, 1997; Rozet at al., 1998; Nasonkin et al., 1998). 35 The large size of this protein (2436 amino acids and 11 WO 01/21798 PCT/US00/40789 calculated MW - 270 kDa) makes this protein one of the largest ABC transporters reported to date. The extracellular loop between the first two transmembrane segments together with the regulatory domain account for 5 the size difference compared to other full-size transporters. ABCA2 has a large number of possible sites for both glycosylation and phosphorylation. A total number of 21 putative glycosylation sites, confirms the glycolytic 10 character of the protein and suggests that functional regulation may be accomodated by phosphokinases. The activity of a related abc transporter, ABCA1 is upregulated in vitro upon treatment with protein kinase A (Becq et al.,1997), implying a possible similar role in 15 ABCA2. The distribution of ABCA2 shows prevalence of expression in the central nervous system, brain and spinal cord. This is in agreement with the data of Luciani and colleagues who showed similar tissue 20 distribution of mouse abca2 (Luciani et al., 1994). Lower expression is observed in lymphoid tissue, such as appendix and spleen together with thyroid gland. So far, several ABC transporters have been identified in the blood-brain barrier (e.g. p-glycoprotein, MRPI) and 25 their role in the transport of xenobiotics is well characterized. ABCA2 may have a similar role in brain. However, although its prevalence in neuronal tissue supports an important role for ABCA2 in this tissue, its presence in other tissues suggests a more pleiotropic 30 role for this transporter. This concept is further supported by the broad expression pattern in the tumor cell lines examined. High ABCA2 levels may be linked to the transformed phenotype or to the physical characteristics of growing cells in vitro. Expression may 35 also be influenced by maturation and/or hormone changes 12 WO01/21798 PCTIUS00/40789 since transcript levels in mouse uterus increase significantly during pregnancy (Luciani et al.,) and in adult compared to fetal brain. In a number of cases, ABC transporters have been 5 shown to participate in active transport of a variety of drugs, lipids, metabolites and peptides (Endicott and Ling, 1989; Hettema et al., 1996; Ewart et al., 1994; Berkow and Michaelis, 1991; Powis et al., 1992). The data from our earlier study on estramustine-resistance 10 clearly implicate ABCA2 in resistance to this drug in an ovarian carcinoma cell line (Laing et al., 1998). Estramustine is a synthetic nitrogen mustard derivative of estradiol with an unexpected antimitotic activity. Thus although it cannot be a natural substrate for ABCA2, 15 it maintains a structural similarity to the steroid estradiol (Punzi et al., 1992). Another possible clue to function of ABCA2 is the presence of lipocalin signature motifs in the regulatory domain of protein. Lipocalins are a family of proteins linked to transport of 20 retinoids, steroids (including cholesterol) lipids and bilins (Flower, 1996). They are characterized by the presence of an eight anti-parallel beta sheet peptide conformation ( - 200 amino acids long) that form a binding site for the hydrophobic substrates. Perhaps not 25 coincidentally, the locus of some members of this family is on 9q34, were ABCA2 resides. In addition, ABCA2 similar proteins (ABCA1 and ABCA4) are involved in the transport of retinoids and cholesterol. Thus, it is likely that steroid, lipid or other similar substrates 30 bind to this lipocalin component of ABCA2, facilitating their transport. Alternatively, the high CNS expression of the transporter may imply that substrates such as neurotransmitters, ions and/or bioacive peptides or amino acids are transported by ABCA2 protein. 35 13 WU u1IL1IV PCT/US00/40789 I. Preparation of ABCA2-Encoding Nucleic Acid Molecules, ABCA2 Proteins, and Antibodies Thereto A. Nucleic Acid Molecules Nucleic acid molecules encoding the ABCA2 proteins 5 of the invention may be prepared by two general methods: (1) synthesis from appropriate nucleotide triphosphates, or (2) isolation from biological sources. Both methods utilize protocols well known in the art. The availability of nucleotide sequence information, such as 10 cDNAs having Sequence I.D. No. 1 enables preparation of an isolated nucleic acid molecule of the invention by oligonucleotide synthesis. Synthetic oligonucleotides may be prepared by the phosphoramidite method employed in the Applied Biosystems 38A DNA Synthesizer or similar 15 devices. The resultant construct may be purified according to methods known in the art, such as high performance liquid chromatography (HPLC). Long, double-stranded polynucleotides, such as a DNA molecule of the present invention, must be synthesized in stages, 20 due to the size limitations inherent in current oligonucleotide synthetic methods. Thus, for example, a 5 kb double-stranded molecule may be synthesized as several smaller segments of appropriate complementarity. Complementary segments thus produced may be annealed such 25 that each segment possesses appropriate cohesive termini for attachment of an adjacent segment. Adjacent segments may be ligated by annealing cohesive termini in the presence of DNA ligase to construct an entire 5 kb double-stranded molecule. A synthetic DNA molecule so 30 constructed may then be cloned and amplified in an appropriate vector. Nucleic acid sequences encoding the ABCA2 proteins of the invention may be isolated from appropriate biological sources using methods known in the art. In a 35 preferred embodiment, a cDNA clone is isolated from a 14 WO 01/21798 PCT/US00/40789 cDNA expression library of human origin. In an alternative embodiment, utilizing the sequence information provided by the cDNA sequence, human genomic clones encoding ABCA2 proteins may be isolated. 5 Alternatively, cDNA or genomic clones having homology with ABCA2 may be isolated from other species using oligonucleotide probes corresponding to predetermined sequences within the ABCA2 encoding nucleic acids. In accordance with the present invention, nucleic 10 acids having the appropriate level of sequence homology with the protein coding region of Sequence I.D. Nos. 1 may be identified by using hybridization and washing conditions of appropriate stringency. For example, hybridizations may be performed, according to the method 15 of Sambrook et al., (supra) using a hybridization solution comprising: 5X SSC, 5X Denhardt's reagent, 1.0% SDS, 100 pg/ml denatured, fragmented salmon sperm DNA, 0.05% sodium pyrophosphate and up to 50% formamide. Hybridization is carried out at 37-42'C for at least six 20 hours. Following hybridization, filters are washed as follows: (1) 5 minutes at room temperature in 2X SSC and 1% SDS; (2) 15 minutes at room temperature in 2X SSC and 0.1% SDS; (3) 30 minutes-1 hour at 37 0 C in 1X SSC and 1% SDS; (4) 2 hours at 42-65 0 in 1X SSC and 1% SDS, changing 25 the solution every 30 minutes. Nucleic acids of the present invention may be maintained as DNA in any convenient cloning vector. In a preferred embodiment, clones are maintained in a plasmid cloning/expression vector, such as pBluescript 30 (Stratagene, La Jolla, CA), which is propagated in a suitable E. coli host cell. ABCA2-encoding nucleic acid molecules of the invention include cDNA, genomic DNA, RNA, and fragments thereof which may be single- or double-stranded. Thus, 35 this invention provides oligonucleotides (sense or 15 WOU01/21798 PCT/US00/40789 antisense strands of DNA or RNA) having sequences capable of hybridizing with at least one sequence of a nucleic acid molecule of the present invention, such as selected segments of the cDNA having Sequence I.D. No. 1. Such 5 oligonucleotides are useful as probes for detecting or isolating ABCA2 genes. Antisense nucleic acid molecules may be targeted to translation initiation sites and/or splice sites to inhibit the translation of the ABCA2-encoding nucleic acids of the invention. Such 10 antisense molecules are typically between 15 and 30 nucleotides and length and often span the translational start site of ABCA2 encoding mRNA molecules. Nucleic acid sequences encoding antisense molecules corresponding to amino acids 1-10, 1-45, 1-50, 1-100 and 1-500 of SEQ 15 ID NO: 2 are thus contemplated to be within the scope of the present invention. It will be appreciated by persons skilled in the art that variants of these sequences exist in the human population, and must be taken into account when designing 20 and/or utilizing oligos of the invention. Accordingly, it is within the scope of the present invention to encompass such variants, with respect to the ABCA2 sequences disclosed herein or the oligos targeted to specific locations on the respective genes or RNA 25 transcripts. With respect to the inclusion of such variants, the term "natural allelic variants" is used herein to refer to various specific nucleotide sequences and variants thereof that would occur in a human population. The usage of different wobble codons and 30 genetic polymorphisms which give rise to conservative or neutral amino acid substitutions in the encoded protein are examples of such variants. Additionally, the term "substantially complementary or homologous" refers to nucleic acid sequences that may not be perfectly matched 35 to a target sequence, but the mismatches do not 16 WO UI01/21798 PCT/US00/40789 materially affect the ability of the oligo to hybridize with its target sequence under the conditions described. B. Proteins 5 Full-length ABCA2 proteins of the present invention may be prepared in a variety of ways, according to known methods. The proteins may be purified from appropriate sources, e.g., transformed bacterial or animal cultured cells or tissues, by immunoaffinity purification. 10 However, this is not a preferred method due to the low amount of protein likely to be present in a given cell type at any time. The availability of nucleic acid molecules encoding ABCA2 proteins enables production of the proteins using in vitro expression methods known in 15 the art. For example, a cDNA or gene may be cloned into an appropriate in vitro transcription vector, such as pSP64 or pSP65 for in vitro transcription, followed by cell-free translation in a suitable cell-free translation system, such as wheat germ or rabbit reticulocytes. In 20 vitro transcription and translation systems are commercially available, e.g., from Promega Biotech, Madison, Wisconsin or Gibco-BRL, Gaithersburg, Maryland. Alternatively, according to a preferred embodiment, larger quantities of ABCA2 proteins may be produced by 25 expression in a suitable prokaryotic or eukaryotic system. For example, part or all of a DNA molecule, such as a cDNA having Sequence I.D. No. 1, may be inserted into a plasmid vector adapted for expression in a bacterial cell, such as E. coli. Such vectors comprise 30 the regulatory elements necessary for expression of the DNA in the host cell positioned in such a manner as to permit expression of the DNA in the host cell. Such regulatory elements required for expression include promoter sequences, transcription initiation sequences 35 and, optionally, enhancer sequences. 17 WU 01/21798 PCT/US00/40789 The human ABCA2 proteins produced by gene expression in a recombinant prokaryotic or eukaryotic system may be purified according to methods known in the art. In a preferred embodiment, a commercially available 5 expression/secretion system can be used, whereby the recombinant protein is expressed and thereafter secreted from the host cell, to be easily purified from the surrounding medium. If expression/secretion vectors are not used, an alternative approach involves purifying the 10 recombinant protein by affinity separation, such as by immunological interaction with antibodies that bind specifically to the recombinant protein or nickel columns for isolation of recombinant proteins tagged with 6-8 histidine residues at their N-terminus or C-terminus. 15 Alternative tags may comprise the FLAG epitope or the hemagglutinin epitope. Such methods are commonly used by skilled practitioners. The human ABCA2 proteins of the invention, prepared by the aforementioned methods, may be analyzed according 20 to standard procedures. For example, such proteins may be subjected to amino acid sequence analysis, according to known methods. As mentioned above, the human ABCA2 encoding nucleic acid of the invention may include a sequence that differs 25 slightly from the SEQ ID NO:l, yet encodes a polypeptide having the same amino acid sequence. Alternatively, the encoded polypeptide may comprise an amino acid sequence which differs by one or more amino acid residues from those shown in SEQ ID NO: 2. Nucleic acid encoding a 30 polypeptide which is an amino acid sequence mutant, variant or derivative of the sequence shown is further provided by the present invention. Nucleic acid encoding such a polypeptide may show at the nucleotide sequence and/or encoded amino acid level greater than about 60% 35 homology with the relevant coding or encoded sequence 18 WO01/21798 PCT/US00/40789 shown herein, greater than about 70% homology, greater than about 80% homology, greater than 90% homology and preferably greater than 95% homology to the sequences provided herein. For amino acid "homology", this may be 5 understood to be similarity (according to established principles of amino acid similarity), e.g., as determined using the algorithm GAP (Genetics Computer Group, Madison, WI) or identity. GAP uses the Needleman and Wunsch algorithm to align two complete sequences that 10 maximizes the number of matches and minimizes the number of gaps. Generally, the default parameters are used, with a gap creation penalty = 12 and gap extension penalty = 4. Use of GAP may be preferred but other algorithms may be used, e.g., BLAST (which uses the 15 method of Altschul et al, (1990) J. Mol. Biol. 215: 405 410), FASTA (which uses the method of Pearson and Lipman (1988) PNAS USA 85:2444-2448), or the Smith-Waterman algorithm (Smith and Waterman (1981) J. Mol. Biol. 147:195-197), generally employing default parameters. 20 Use of either of the terms "homology" and "homologous" herein does not imply any necessary evolutionary relationship between compared sequence in keeping with the meaning of the term as used in the phrase "homologous recombination". As is well known to those of skill in 25 the art, homologous recombination merely requires that two nucleotide sequences be sufficiently similar to recombine under the appropriate conditions. The present invention also provides antibodies capable of immunospecifically binding to proteins of the 30 invention. Polyclonal antibodies directed toward human ABCA2 proteins may be prepared according to standard methods. In a preferred embodiment, monoclonal antibodies are prepared, which react immunospecifically with the various epitopes of the ABCA2 proteins described 35 herein. Monoclonal antibodies may be prepared according 19 WU U01/21798 PCT/US00/40789 to general methods of K6hler and Milstein, following standard protocols. Polyclonal or monoclonal antibodies that immunospecifically interact with ABCA2 proteins can be utilized for identifying and purifying such proteins. 5 For example, antibodies may be utilized for affinity separation of proteins with which they immunospecifically interact. Antibodies may also be used to immunoprecipitate proteins from a sample containing a mixture of proteins and other biological molecules. 10 Other uses of anti-ABCA2 antibodies are described below. II. Uses of ABCA2-Encoding Nucleic Acids, ABCA2 Proteins and Antibodies Thereto Cellular transporter molecules have received a great 15 deal of attention as potential targets of therapeutic agents designed to effectively block the export of, or promote import of pharmacological reagents across cell membranes. The ABCA2 proteins of the invention play a pivotal role in cellular transport. 20 Additionally, ABCA2 nucleic acids, proteins and antibodies thereto, according to this invention, may be used as research tools to identify other proteins that are intimately involved in the transport of molecules into and out of cells. Biochemical elucidation of 25 molecular mechanisms which govern such transport will facilitate the development of novel anti-transport agents that may, for example, sensitize tumor cells to conventional chemotherapeutic agents. 30 A. ABCA2-Encoding Nucleic Acids ABCA2-encoding nucleic acids may be used for a variety of purposes in accordance with the present invention. ABCA2-encoding DNA, RNA, or fragments thereof may be used as probes to detect the presence of and/or 35 expression of genes encoding ABCA2 proteins. Methods in 20 WO 01/21798 PCT/US00/40789 which ABCA2-encoding nucleic acids may be utilized as probes for such assays include, but are not limited to: (1) in situ hybridization; (2) Southern hybridization (3) northern hybridization; and (4) assorted amplification 5 reactions such as polymerase chain reactions (PCR). The ABCA2-encoding nucleic acids of the invention may also be utilized as probes to identify related genes from other animal species. As is well known in the art, hybridization stringencies may be adjusted to allow 10 hybridization of nucleic acid probes with complementary sequences of varying degrees of homology. Thus, ABCA2-encoding nucleic acids may be used to advantage to identify and characterize other genes of varying degrees of relation to the ABCA2 genes of the invention. Such 15 information enables further characterization of transporter molecules which give rise to the chemoresistant phenotype of certain tumors. Additionally, they may be used to identify genes encoding proteins that interact with ABCA2 proteins (e.g., by the 20 "interaction trap" technique), which should further accelerate identification of the components involved in transport of biological molecules across cell membranes. The ABCA2-encoding nucleic acids may also be used to generate primer sets suitable for PCR amplification of 25 target ABCA2 DNA. Criteria for selecting suitable primers are well known to those of ordinary skill in the art. Nucleic acid molecules, or fragments thereof, encoding ABCA2 genes may also be utilized to control the 30 production of ABCA2 proteins, thereby regulating the amount of protein available to participate in biological or pharmacological reagent transport. As mentioned above, antisense oligonucleotides corresponding to essential processing sites in ABCA2-encoding mRNA 35 molecules may be utilized to inhibit ABCA2 protein 21 WU UI/21798 PCTUS00/40789 production in targeted cells. Alterations in the physiological amount of ABCA2 proteins may dramatically affect the ability of these proteins to transport pharmacological reagents out of the cell. 5 Host cells comprising ABCA2-encoding DNA molecules are encompassed in the present invention. Host cells contemplated for use in the present invention include but are not limited to bacterial cells, fungal cells, insect cells, mammalian cells, and plant cells. Methods for 10 introducing DNA molecules are also well known to those of ordinary skill in the art. Such methods are set forth in Ausubel et al. eds., Current Protocols in Molecular Biologv, John Wiley & Sons, NY, NY 1995, the disclosure of which is incorporated by reference herein. 15 The availability of ABCA2-encoding nucleic acids enables the production of strains of laboratory mice carrying part or all of the ABCA2 gene or mutated sequences thereof. Such mice may provide an in vivo model for development of novel therapeutic agents. 20 Alternatively, the ABCA2 nucleic acid sequence information provided herein enables the production of knockout mice in which the endogenous gene encoding ABCA2 has been specifically inactivated. Methods of introducing transgenes in laboratory mice are known to 25 those of skill in the art. Three common methods include: 1. integration of retroviral vectors encoding the foreign gene of interest into an early embryo; 2. injection of DNA into the pronucleus of a newly fertilized egg; and 3. the incorporation of genetically 30 manipulated embryonic stem cells into an early embryo. The alterations to the ABCA2 gene envisioned herein include modifications, deletions, and substitutions. Modifications and deletions render the naturally occurring gene nonfunctional, producing a "knock out" 35 animal. Substitutions of the naturally occurring gene 22 WO01/21798 PCT/US00/40789 for a gene from a second species results in an animal which produces an ABCA2 gene from the second species. Substitution of the naturally occurring gene for a gene having a mutation results in an animal with a mutated 5 ABCA2 protein. A transgenic mouse carrying the human ABCA2 gene is generated by direct replacement of the mouse ABC2 gene with the human gene. These transgenic animals are valuable for use in in vivo assays for elucidation of other medical disorders associated with 10 cellular activities modulated by the ABCA2 gene. A transgenic animal carrying a "knock out" of an ABCA2 encoding nucleic acid is useful for the establishment of a nonhuman model for chemotherapy resistance involving ABCA2 regulation. 15 As a means to define the role that ABCA2 plays in mammalian systems, mice can be generated that cannot make ABCA2 proteins because of a targeted mutational disruption of the ABCA2 gene. The term "animal" is used herein to include all 20 vertebrate animals, except humans. It also includes an individual animal in all stages of development, including embryonic and fetal stages. A "transgenic animal" is any animal containing one or more cells bearing genetic information altered or received, directly or indirectly, 25 by deliberate genetic manipulation at the subcellular level, such as by targeted recombination or microinjection or infection with recombinant virus. The term "transgenic animal" is not meant to encompass classical cross-breeding or in vitro fertilization, but 30 rather is meant to encompass animals in which one or more cells are altered by or receive a recombinant DNA molecule. This molecule may be specifically targeted to a defined genetic locus, be randomly integrated within a chromosome, or it may be extrachromosomally replicating 35 DNA. The term "germ cell line transgenic animal" refers 23 Wo UI/ZI798 PCT/US00/40789 to a transgenic animal in which the genetic alteration or genetic information was introduced into a germ line cell, thereby conferring the ability to transfer the genetic information to offspring. If such offspring in fact, 5 possess some or all of that alteration or genetic information, then they, too, are transgenic animals. The alteration or genetic information may be foreign to the species of animal to which the recipient belongs, or foreign only to the particular individual recipient, 10 or may be genetic information already possessed by the recipient. In the last case, the altered or introduced gene may be expressed differently than the native gene. The altered ABCA2 gene generally should not fully encode the same ABCA2 protein native to the host animal and its 15 expression product should be altered to a minor or great degree, or absent altogether. However, it is conceivable that a more modestly modified ABCA2 gene will fall within the compass of the present invention if it is a specific alteration. 20 The DNA used for altering a target gene may be obtained by a wide variety of techniques that include, but are not limited to, isolation from genomic sources, preparation of cDNAs from isolated mRNA templates, direct synthesis, or a combination thereof. 25 A preferred type of target cell for transgene introduction is the embryonal stem cell (ES). ES cells may be obtained from pre-implantation embryos cultured in vitro. Transgenes can be efficiently introduced into the ES cells by standard techniques such as DNA transfection 30 or by retrovirus-mediated transduction. The resultant transformed ES cells can thereafter be combined with blastocysts from a non-human animal. The introduced ES cells thereafter colonize the embryo and contribute to the germ line of the resulting chimeric animal. 35 One approach to the problem of determining the 24 WO01/21798 PCTUS00/40789 contributions of individual genes and their expression products is to use an isolated ABCA2-encoding nucleic acid to selectively inactivate the wild-type gene in totipotent ES cells (such as those described above) and 5 then generate transgenic mice. The use of gene-targeted ES cells in the generation of gene-targeted transgenic mice is known in the art. Techniques are available to inactivate or alter any genetic region to a mutation desired by using targeted 10 homologous recombination to insert specific changes into chromosomal alleles. However, in comparison with homologous extrachromosomal recombination, which occurs at a frequency approaching 100%, homologous plasmid chromosome recombination was originally reported to only 15 be detected at frequencies between 106 and 10'. Nonhomologous plasmid-chromosome interactions are more frequent occurring at levels 10 5 -fold to 10 2 -fold greater than comparable homologous insertion. To overcome this low proportion of targeted 20 recombination in murine ES cells, various strategies have been developed to detect or select rare homologous recombinants. One approach for detecting homologous alteration events uses the polymerase chain reaction (PCR) to screen pools of transformant cells for 25 homologous insertion, followed by screening of individual clones. Alternatively, a positive genetic selection approach has been developed in which a marker gene is constructed which will only be active if homologous insertion occurs, allowing these recombinants to be 30 selected directly. One of the most powerful approaches developed for selecting homologous recombinants is the positive-negative selection (PNS) method developed for genes for which no direct selection of the alteration exists. The PNS method is more efficient for targeting 35 genes which are not expressed at high levels because the 25 WU U01/21798 PCT/US00/40789 marker gene has its own promoter. Non-homologous recombinants are selected against by using the Herpes Simplex virus thymidine kinase (HSV-TK) gene and selecting against its nonhomologous insertion with 5 effective herpes drugs such as gancyclovir (GANC) or (1 (2-deoxy-2-fluoro-B-D arabinofluranosyl)-5-iodouracil, (FIAU). By this counter selection, the number of homologous recombinants in the surviving transformants can be increased. 10 As used herein, a "targeted gene" or "knock-out" is a DNA sequence introduced into the germline or a non human animal by way of human intervention, including but not limited to, the methods described herein. The targeted genes of the invention include DNA sequences 15 which are designed to specifically alter cognate endogenous alleles. Methods of use for the transgenic mice of the invention are also provided herein. Knockout mice of the invention can be injected with tumor cells or treated 20 with carcinogens to generate carcinomas. Such mice provide a biological system for assessing chemotherapy resistance as modulated by an ABCA2 gene of the invention. Accordingly, therapeutic agents which inhibit the action of these transporters and thereby prevent 25 efflux of beneficial chemotherapeutic agents from tumor cells may be screened in studies using ABCA2 knock out mice. As described above, ABCA2-encoding nucleic acids are also used to advantage to produce large quantities of 30 substantially pure ABCA2 proteins, or selected portions thereof. 35 26 WO U1/21798 PCTUS00/40789 B. ABCA2 Proteins and Antibodies Purified full length ABCA2 proteins, or fragments thereof, may be used to produce polyclonal or monoclonal antibodies which also may serve as sensitive detection 5 reagents for the presence and accumulation of ABCA2 proteins (or complexes containing ABCA2 proteins) in mammalian cells. Recombinant techniques enable expression of fusion proteins containing part or all of ABCA2 proteins. The full length proteins or fragments of 10 the proteins may be used to advantage to generate an array of monoclonal antibodies specific for various epitopes of ABCA2 proteins, thereby providing even greater sensitivity for detection of ABCA2 proteins in cells. 15 Polyclonal or monoclonal antibodies immunologically specific for ABCA2 proteins may be used in a variety of assays designed to detect and quantitate the proteins. Such assays include, but are not limited to: (1) flow cytometric analysis; (2) immunochemical 20 localization of ABCA2 proteins in tumor cells; and (3) immunoblot analysis (e.g., dot blot, Western blot) of extracts from various cells. Additionally, as described above, anti-ABCA2 antibodies can be used for purification of ABCA2 proteins and any associated subunits (e.g., 25 affinity column purification, immunoprecipitation). From the foregoing discussion, it can be seen that ABCA2-encoding nucleic acids, ABCA2 expressing vectors, ABCA2 proteins and anti-ABCA2 antibodies of the invention can be used to detect ABCA2 gene expression and alter 30 ABCA2 protein accumulation for purposes of assessing the genetic and protein interactions involved in the transport of biological and pharmacological reagents across cell membranes. 35 27 WO01/21798 PCTIUS00/40789 C. Methods and Kits Employing the Compositions of the Present Invention Methods and kits encompassing the human ABCA2 encoding nucleic acids of the invention are also 5 contemplated to be within the scope of the present invention. Exemplary approaches for detecting ABCA2 nucleic acid or polypeptides/proteins include: a) comparing the sequence of nucleic acid in the 10 sample with the ABCA2 nucleic acid sequence to determine whether the sample from the patient contains mutations; or b) determining the presence, in a sample from a patient, of the polypeptide encoded by the ABCA2 gene 15 and, if present, determining whether the polypeptide is full length, and/or is mutated, and/or is expressed at the normal level; or c) using DNA restriction mapping to compare the restriction pattern produced when a restriction enzyme 20 cuts a sample of nucleic acid from the patient with the restriction pattern obtained from normal ABCA2 gene or from known mutations thereof; or, d) using a specific binding member capable of binding to a ABCA2 nucleic acid sequence (either normal 25 sequence or known mutated sequence), the specific binding member comprising nucleic acid hybridizable with the ABCA2 sequence, or substances comprising an antibody domain with specificity for a native or mutated ABCA2 nucleic acid sequence or the polypeptide encoded by it, 30 the specific binding member being labeled so that binding of the specific binding member to its binding partner is detectable; or, e) using PCR involving one or more primers based on normal or mutated ABCA2 gene sequence to screen for 28 WU UI/ZI798 PCT/US00/40789 normal or mutant ABCA2 gene in a sample from a patient. A "specific binding pair" comprises a specific binding member (sbm) and a binding partner (bp) which have a particular specificity for each other and which in 5 normal conditions bind to each other in preference to other molecules. Examples of specific binding pairs are antigens and antibodies, ligands and receptors and complementary nucleotide sequences. The skilled person is aware of many other examples and they do not need to be 10 listed here. Further, the term "specific binding pair" is also applicable where either or both of the specific binding member and the binding partner comprise a part of a large molecule. In embodiments in which the specific binding pair are nucleic acid sequences, they will be of 15 a length to hybridize to each other under conditions of the assay, preferably greater than 10 nucleotides long, more preferably greater than 15 or 20 nucleotides long. In most embodiments for screening for alleles giving rise to chemotherapy resistance, for example, the ABCA2 20 nucleic acid in biological sample will initially be amplified, e.g. using PCR, to increase the amount of the analyte as compared to other sequences present in the sample. This allows the target sequences to be detected with a high degree of sensitivity if they are present in 25 the sample. This initial step may be avoided by using highly sensitive array techniques that are becoming increasingly important in the art. The identification of the full-length ABCA2-encoding nucleic acid, and its association with a particular 30 chemotherapy resistance paves the way for aspects of the present invention to provide the use of materials and methods, such as are disclosed and discussed above, for establishing the presence or absence in a test sample of a variant form of the gene, in particular an allele or 35 variant specifically associated with chemotherapy 29 WU UIZI79 PCT/US00/40789 resistance. This may be done to assess the propensity of the tumor to exhibit chemotherapy resistance. Alternatively, ABCA2 mutations may result in aberrant transport of endogenous biological molecules 5 resulting in a pathological condition. For example, Rozet and colleagues have identified a spectrum of ABCA4 gene mutations associated with autosomal recessive macular dystrophies. Rozet et al., 1998). Mutations in another ABC transporter, ABCA1, have been linked to 10 Tangier disease (Rust et al., 1998). In a similar fashion, it is likely that mutations in the ABCA2 gene are associated certain pathological conditions. Thus, methods to identify such mutations are contemplated to be within the scope of the present invention. 15 In still further embodiments, the present invention concerns immunodetection methods for binding, purifying, removing, quantifying or otherwise generally detecting biological components. The encoded proteins or peptides of the present invention may be employed to detect 20 antibodies having reactivity therewith, or, alternatively, antibodies prepared in accordance with the present invention, may be employed to detect the encoded proteins or peptides. The steps of various useful immunodetection methods have been described in the 25 scientific literature, such as, e.g., Nakamura et al. (1987). In general, the immunobinding methods include obtaining a sample suspected of containing a protein, peptide or antibody, and contacting the sample with an 30 antibody or protein or peptide in accordance with the present invention, as the case may be, under conditions effective to allow the formation of immunocomplexes. The immunobinding methods include methods for detecting or quantifying the amount of a reactive 35 component in a sample, which methods require the 30 WU UI/217Z8 PCT/US00/40789 detection or quantitation of any immune complexes formed during the binding process. Here, one would obtain a sample suspected of containing an ABCA2 gene encoded protein, peptide or a corresponding antibody, and contact 5 the sample with an antibody or encoded protein or peptide, as the case may be, and then detect or quantify the amount of immune complexes formed under the specific conditions. In terms of antigen detection, the biological sample 10 analyzed may be any sample that is suspected of containing the ABCA2 antigen, such as a tumor tissue section or specimen, a homogenized tissue extract, an isolated cell, a cell membrane preparation, separated or purified forms of any of the above protein-containing 15 compositions. Contacting the chosen biological sample with the protein, peptide or antibody under conditions effective and for a period of time sufficient to allow the formation of immune complexes (primary immune complexes) 20 is generally a matter of simply adding the composition to the sample and incubating the mixture for a period of time long enough for the antibodies to form immune complexes with, i.e., to bind to, any antigens present. After this time, the sample-antibody composition, such as 25 a tissue section, ELISA plate, dot blot or Western blot, will generally be washed to remove any non-specifically bound antibody species, allowing only those antibodies specifically bound within the primary immune complexes to be detected. 30 In general, the detection of immunocomplex formation is well known in the art and may be achieved through the application of numerous approaches. These methods are generally based upon the detection of a label or marker, such as any radioactive, fluorescent, biological or 35 enzymatic tags or labels of standard use in the art. U.S. 31 WU Ul/n17Y9 PCT/US00/40789 Patents concerning the use of such labels include U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149 and 4,366,241, each incorporated herein by reference. Of course, one may find additional 5 advantages through the use of a secondary binding ligand such as a second antibody or a biotin/avidin ligand binding arrangement, as is known in the art. In one broad aspect, the present invention encompasses kits for use in detecting expression of 10 ABCA2-encoding nucleic acids in biological samples, including biopsy samples. Such a kit may comprise one or more pairs of primers for amplifying nucleic acids corresponding to the ABCA2 gene. The kit may further comprise samples of total mRNA derived from tissues 15 expressing the ABCA2-encoding nucleic acid of the invention, to be used as controls. The kit may also comprise buffers, nucleotide bases, and other compositions to be used in hybridization and/or amplification reactions. Each solution or composition may 20 be contained in a vial or bottle and all vials held in close confinement in a box for commercial sale. In a further embodiment, the invention encompasses a kit for use in detecting ABCA2 proteins in chemotherapy resistant cancer cells comprising antibodies specific for ABCA2 25 proteins encoded by the ABCA2 nucleic acids of the present invention. Another aspect of the present invention comprises screening methods employing host cells expressing an ABCA2-encoding nucleic acid of the invention. An 30 advantage of having discovered the complete coding sequence of ABCA2 is that cell lines that overexpress ABCA2 can be generated using standard transfection protocols. Cells that overexpress the complete cDNA will also harbor the complete proteins a feature that is 35 essential for 32 WO01/21798 PCTIUS00/40789 assessing biological activity of the protein. The overexpressing cell lines will be useful in several ways: l)The drug sensitivity of overexpressing cell lines can be tested with a variety of known anticancer agents in 5 order to determine the spectrum of anticancer agents for which the transporter confers resistance; 2)The drug sensitivity of overexpressing cell lines can be used to determine whether newly discovered anticancer agents are transported out of the cell by one of the discovered 10 transporters; 3)Overexpressing cell lines can be used to identify potential inhibitors that reduce the activity of the transporters. Such inhibitors are of great clinical interest in that they may enhance the activity of known anticancer agents, thereby increasing their 15 effectiveness. Reduced activity will be detected by restoration of anticancer drug sensitivity, or by reduction of transporter mediated cellular efflux of anticancer agents. In vitro biochemical studies designed to identify reduced transporter activity in the presence 20 of potential inhibitors can also be performed using membranes prepared from overexpessing cell lines; and 4)Overexpressing cell lines can also be used to determine whether pharmaceutical agents that are not anticancer agents are transported out of the cell by the 25 transporters. The following protocols are provided to facilitate the practice of the present invention. Isolation of ABCA2 cDNA 30 We cloned the ABCA2 cDNA using a variety of library screening and PCR-based approaches. As previously reported (Laing et al., 1998), we first isolated 1.75 kb of ABCA2 cDNA by PCR using primers designed against the expressed sequence tag representing human ABCA2 (EST0600) 35 and mouse abca2 cDNA (GenBank Accession number X75927). 33 Wo U1/21798 PCTUS00/40789 Our initial library screening experiments were performed using a ready-made random and oligo(dT)-primed human fetal brain cDNA library generated in lambda ZAP II (Stratagene, La Jolla, CA). This library was chosen 5 because ABCA2 expression in mouse is most pronounced in brain (Luciani et al., 1994). The library was probed with a 32 P-labeled (Prime-it II Random Primer Labeling Kit, Stratagene, La Jolla, CA) 490 bp PCR fragment that we amplified from the 5' end of the 1.75 kb ABCA2 10 fragment. Screening was performed according to the manufacturer's instructions. In brief, XLI-Blue bacteria were incubated with different dilutions of library and plated onto LB plates to titer the library. After plating 50,000 pfu /150 mm plate and subsequent 15 incubations, colonies were transferred to nitrocellulose filters, which were then denatured, neutralized and washed. DNA was cross-linked to the filters and they were then prehybridized for at least 2 h at 65'C and hybridized overnight. After post-hybridization washing, 20 filters were autoradiographed to identify positives. The four longest ABCA2 clones were designated as X15B, 17B, X5A, X9A. See Figure 1. 5' RACE using nested-PCR was performed using human brain Marathon-Ready adapter-ligated cDNA as template 25 (Clontech, Palo Alto, CA). The first round of PCR used adapter primer 1 (APl) 5'-CCATCCTAATACGACTCACTATAGGGC-3' (forward; Sequence I.D. No. 3) and ABCA2 specific 5' TGAGTTTGTCCACGCAGACAACCAGAG-3' (reverse; Sequence I.D. No. 4); adapter primer 2 (AP2) 5' 30 ACTCACTATAGGGCTCGAGCGGC-3' (forward; Sequence I.D. No. 5) with ABCA2 specific 5'-CCAGCTCCACTCCCAGGCTTCTG-3' (reverse; Sequence I.D. No. 6). The products were ligated into the pT-Adv plasmid (Clontech, Palo Alto, CA) and ligation extraction products used to transform 35 TOPO10' cells. Based on additional 5' sequence obtained 34 WO 01/21798 PCT/US00/40789 from this approach, (clone 35, Fig. 1), the following primers were designed for subsequent 5'RACE: AP1 (forward) and 5'-TGAGTTTGTCCACGCAGACAACCAGAG-3' (reverse; Sequence I.D. No. 7); second round PCR used AP2 (forward) 5 and 5'-CCAGCTCCACTCCCAGGCTTCTG-3' (reverse; Sequence I.D. No. 8). The longest clone isolated, designated 208 was -900 bp (Fig. 1). To obtain the entire 5' end sequence, we constructed a 5' ABCA2 cDNA library from high quality human brain 10 poly (A)+ RNA (Clontech, Palo Alto, CA) using Marathon cDNA Amplification Kit (Clontech, Palo Alto, CA). Gene specific primer was used for first strand synthesis. Second strand synthesis and creation of blunt ends was followed by DNA ligation with adapters provided with the 15 kit, according to the manufacturer's protocol. The library was then PCR amplified using AP1 and 5'-CCACTGGG CAGCGAGAAGTTGTC-3' (Sequence I.D. No. 9) followed by amplification with nested ABCA2 primer 5'-GAAGCTGGAGTTCTGGCGGATCT-3' (Sequence I.D. No. 10) and 20 adapter primer, AP2. Reaction products were cloned into pCR-XL-TOPO plasmid (Invitrogen, Carlsbad, CA) and transformed into DH5 a cells. Figure 1 indicates the location of the two longest clones, designated 65 and 119. 25 For 3'RACE, we used: 5'CAGACCACACTGGACAATGTGTTCGTG3' (forward; Sequence I.D. No. 11) and AP1 (reverse); 5' TCATCAGCTTCGAGGAGGAGCGG3' (forward; Sequence I.D. No. 12) and AP2 (reverse). Only short, 300 bp fragments were isolated (data not shown). 30 Full length ABCA2 cDNA was assembled from 4 fragments (A-D). Fragments A and B were obtained by PCR from human brain cDNA library using the following primers: 5'ATAAGCTTGCTGAGGCGGCGGAGCGTGGC3' (Sequence I.D. No. 13) and 5'CCACTGGGCGAGAAGTTGTC3' (Sequence I.D. No. 35 14) for fragment A, and 5'CCTCATTTTCCCCTACAACC3' 35 WU U1/z179 PCTIUS00/40789 (Sequence I.D. No. 15) and 5'ACCTGCTCCATCTTGCTGCTGAACAC, (Sequence I.D. No. 16) for fragment B. Fragment C was directly obtained by restriction digest of KIA1065 clone (kindly provided by Dr Takahiro Nagase from Kazusa 5 DNA Research Institute). Fragment D was obtained by PCR from KIA1065 clone using 5'CAGCGGCGGCAACAAGCGGAA3' (Sequence I.D. No. 17) and 5'GGTGAATTCGGCAGGCACTGGGGGACTTGT3' (Sequence I.D. No. 18) primers. PCR products were initially cloned into 10 pCR-XL-TOPO cloning vector. Fragment A was excised by Hind III and Sal I digest and subcloned into pCR-XL-TOPO clone containing fragment B. Fragment D was excised by Kpn I and EcoR I digestion and subcloned into corresponding sites of (A+B)pCR-XL-TOPO construct. 15 Finally fragment C was cloned into Kpn I site of (A+B+D) pCR-XL-TOPO clone. The full length ABCA2 cDNA was excised from pCR-XL-TOPO-ABCA2 by Hind III and EcoR I digestion and subloned into corresponding sites of pcDNA (3.1+) vector (Invitrogen, Carlsbad, CA). That clone has 20 been designated as pcDNA(3.1+)-ABCA2. pEGFP-ABCA2 clone was constructed in the following way: start codon of ABCA2 was modified using PCR (primers used were 5'TAGTACTCCTTGGGCTTCCTGCACCAGC3'(Sequence I.D. No. 19) and 5'CCAGGGCAGATGAGGGACCAAAGA3' (Sequence I.D. 25 No. 20)), and resulting clone inserted into ScaI and EcoRI sites of pEGFP-C3 vector (Clontech, Palo Alto, CA). All PCR products were verified by double-stranded DNA sequencing. 30 Mapping of transcription start site 5' RACE was used to map the start site of the ABCA2 transcript. Reverse transcription of total brain RNA (Clontech, Palo Alto) was performed using antisense gene specific primer, 5'CATCCAGCAGGTCCCCCAGAAGC 3' (Sequence 35 I.D. No. 21) and was followed by RNase H treatment. The 36 wu U1/a178 PCT/US00/40789 first strand synthesis product was subjected to dC tailing reactions with terminal deoxynucleotidyl transferase. The first round of PCR amplification was then performed using 5' RACE anchor primer 5 5'GGCCACGCGTCGACTAGTACGGGIIGGGIIGGGIIG3' (Sequence I.D. No. 22) and gene-specific antisense primer 5'AAACAGGTTGCCCTTCCTCCACCAC3' (Sequence I.D. No. 23). A second round of PCR amplification was performed with universal amplification primer 5'GGCCACGCGTCGACTAGTAC3' 10 (Sequence I.D. No. 24) and gene specific antisense primer 5'ACAGCGATTGCATGACAGGCAG3' (Sequence I.D. No. 25). A single - 300 bp product was obtained, and after purification it was cloned and sequenced. 15 Northern blot analysis Samples of the total RNA from a selection of NCI panel human tumor cell lines were provided by Dr. Anne Monks (Monks et al., 1991). 10 ig samples were fractionated on formaldehyde agarose gels, transferred to 20 nylon membranes (GeneScreen, NEN, Boston, MA) and hybridized by standard protocols. 32 P radioactive labeling of a gel-purified 1.75 kb ABCA2 probe to high specific activity was performed by random priming kit (Prime-It 11 Random Primer Labeling Kit, Stratagene, La 25 Jolla, CA). A multiple human tissue poly(A)+RNA dot blot (MTE Array, Clontech, Palo Alto, CA), and Multiple Tissue Northern Blot (MTN, Clontech, Palo, Alto, CA) were hybridized with a 870 bp probe that was PCR amplified 30 using the following primers: 5' AGGGAGCTGGCTACACCGACG 3' (forward; Sequence I.D. No. 26) and 5'CGCCTGTGACCACCCGCATCT 3' (reverse; Sequence I.D. No. 27). Portions were biotin-labeled (for MTE Array screen) or 32 P radioactive labeled (for MTN screen) according to 35 the random primer labeling method. Non-radioactive 37 WO01/21798 PCT/US00/40789 detection was performed with North 2 South Chemiluminescent Detection system (Pierce, Rockford, IL). The signal intensities were quantified with NIH Image software. 5 ABCA2 sequence analysis Nucleotide sequencing was performed with an ABI 377 DNA sequencer. The sequences were assembled in the Sequencher program (Gene Codes Corporation, Ann Arbor, 10 MI). Protein computer analyses were performed with the Genetics Computer Group Package version 9.1 (Madison, WI), and McVector (Oxford Molecular). The following example is provided to illustrate an 15 embodiment of the invention. It is not intended to limit the invention in any way. EXAMPLE I Cloning of human ABCA2 20 The ABCA2 transporter was cloned by initially screening an oligo(dT) and random primed human fetal brain cDNA library probed with a PCR-amplified 1.75 kb fragment of ABCA2 (Laing et al., 1998). Out of four isolated clones, the longest, lambda ?9A, was 4.8 kb in 25 length (Fig. 1). This fragment showed 86% nucleotide identity to the 4.7 kb of available mouse ABCA2 with the least homology in the last 300 bp, and no predicted in-frame stop codon. Initial 5' RACE yielded another -1.4 kb of sequence at the 5 'end of ABCA2 cDNA from the 30 longest overlapping clones, 35 and 208 (Fig. 1). We created our own human brain Marathon cDNA using gene specific primers near the 5' end in order to obtain an ATG start codon with apparent Kozak sequence. The two longest amplified products, 65 and 119, both contained 35 the same 5' UTR and the ATG start in standard Kozak 38 WU U1/21798 PCT/US00/40789 context (Kozak, 1991). 5' RACE was performed to map the transcriptional start site and yielded a single band. Thus, the major transcriptional start site is at a cytosine, 50bp upstream of the translational start site. 5 For the 3' RACE experiment, we used gene specific primers upstream from the predicted stop codon, (based on mouse ORF) (Luciani et al., 1994) and generated a number of 300-400 bp fragments containing putative stop codons and an additional -300 bp of 3'UTR (data not shown). In 10 addition, an interim BLAST search of the sequence of the 19A clone (Fig. 1), returned a brain clone (GenBank number AB028985), with high identity to the last -4.7 kb of this clone and provided in addition to 300 bp, another -400 bp of 3'UTR (Fig. 1). The total sequence assembled 15 resulted in 8056 bp ABCA2 cDNA, with 7308 bp corresponding to ORF, 50 bp 5'UTR and 698 bp 3'UTR (Fig. 1). Comparison of the nucleotide sequences of ABCAl-related proteins to ABCA2 showed that these transporters share 51-52% identity. 20 Primary Structure of ABCA2 Nucleotide analysis revealed that the ABCA2 open reading frame was comprised of 7308 bp and encoded a 2436 amino acid protein with a predicted molecular weight of 25 270 kDa and a pI of 6.4. See Figure 2. Comparison of the ABCA2 primary structure with several other human ABC-transporters, showed that ABCA2 shares 45.4% amino acid identity with ABCA1 and slightly less with ABCA4 (38.5%) and hABCA3 (38.2%) (Table 1). The protein is 30 less similar to other well characterized ABC transporters, such as MDRI (33% identical) and MRP (25% identical). Homology comparison with the partial mouse ABCA2 sequence (Luciani et al., 1994) revealed 94.4% amino acid identity within the published region. The 35 amino terminal of ABCA2 shares high identity with the 39 WO01/21798 PCTIUS00/40789 amino terminal of ABCA4 and ABCA3 (65-70% in the first 20 amino acids), although homology with these proteins drops significantly in adjacent domains of ABCA2. The ATP-binding cassettes of ABCA2 contain conserved 5 Walker A and B ATP-binding motifs together with the signature sequence of ABC transporters (Fig. 3). The amino terminal ABC of ABCA2 is most identical to ABCA1 (70.6%) and slightly less to that of ABCA4 (65.2%) and ABCA3 (58.2%). The carboxy-terminal has highest identity 10 with ABCA4 (67.8%) and ABCA1 (66.1%) and somewhat less with ABCA3 (60.7%). The ABCA2 protein is a full-size transporter that contains a tandem repeat of the recognizable hydrophobic domain with six transmembrane helices followed by highly 15 conserved ATP-binding cassettes. Despite the apparent structural symmetry, there is very little sequence homology between the two halves of the predicted ABCA2 protein, as seen by dot matrix analysis (Fig. 2D). Structurally, the hydrophobic domain spacing is 20 reminiscent of that found in ABCA4 (Figs. 2 B, 2C). The cytosolic N-terminus is immediately followed by the first transmembrane segment and a long extra-cytosolic loop. The long hydrophilic linker portion of the protein (-700 amino acids) is separated into two halves by a highly 25 hydrophobic domain. This region of the protein, as suggested by Luciani and colleagues, may correspond to a putative regulatory domain similar to the one found in CFTR. The potential sites of N-glycosylation are concentrated in two regions, with the first fifteen on 30 the large extracellular loop and the second six between the HHD and the 7th transmembrane segment. While these post-translation modifications are highly probable in the first region, glycosylation at the second region may be more hypothetical, based on the present understanding of 35 ABCl-like proteins (Azarian and Travis, 1997). While 40 WO 01/21798 PCT/US00/40789 some groups (Azarian and Travis, 1997; Rozet et al., 1998) favor a structure in which a highly hydrophobic domain (HHD) is followed by a cytoplasmic segment, thereby negating glycosylation within the second region, 5 Illing and colleagues (Illing et al., 1997) based on peptide analysis, predicted a model in which a glycosylated extracellular loop is present between HHD and the seventh transmembrane segment. Thus, it is possible that the HHD may represent an actual full-span 10 transmembrane segment. A number of potential phosphorylation sites were also apparent, including, protein kinase C, casein kinase, tyrosine kinase and cAMP dependent-protein kinase. Of particular interest to our earlier 15 observation of the potential role of ABCA2 in the transport of steroids (Laing et al., 1998), a lipocalin signature (GQSRKLDGGWLKV) was identified at position 1424 within the putative regulatory domain and close to the HHD. This motif is characteristic of small lipocalin 20 proteins that transport lipids, steroids, bilins and retinoids (Flower, 1996). Table 1. Comparison of amino acid sequences (% identity) between members of ABCI subfamilya 25 ABCA2 ABCA1 ABCA4 ABCA3 MusABCA2 ABCA2 - 45.4 38.5 38.2 94.4 (70.6/66/1) (65.2/67.8) (58.2/60.7) (98.9/95.1) ABCA1 45.4 - 51.8 40.4 51.7 (70.6/66.1) (69.0/73.2) (62.0/55.2) (70.1/66.1) ABCA4 38.5 51.8 - 36.8 43.5 (65.2/67.8) (69.0/73.2) (60.4/59.0) (64.7/67.2) 30 ABCA3 38.2 40.4 36.8 - 42.0 (58.2/60.7) (62.0/55.2) (60.4/59.0) (58.3/60.7) MusABCA2 94.4 51.7 43.5 42.0 (98.9/95.1) (70.1/66.1) (64.7/67.2) (58.3/60.7) 41 WO01/21798 PCTIUS00/40789 aGAP function in GCG software was used to obtain data. Numbers in parentheses represent percent identity of ATP binding cassette 1 and 2 (ABCAl/ABCA2). 5 Human ABCA2 expression pattern Northern analysis of ABCA2 message shows that the ABCA2 transcript is -8 kb in length (Fig. 4). Of the 12 tissues analyzed, ABCA2 expression is highest in the brain. The dot blot analysis confirmed that ABCA2 was 10 most prevalent in the central nervous system (Fig. 5). The highest expressing regions of CNS are spinal cord, corpus callosum, medulla oblongata and thalamus. This expression was higher in adult brain than fetal and there were also significant levels in thyroid gland and 15 lymphoid tissue, such as appendix and spleen. The expression levels in other tissues were rather low. In the NCI cell line panel of tumors, there was a more ubiquitous pattern (Table 2). The SNB-75 cell line was the highest among the CNS; however, the presence of 20 measurable ABCA2 transcript in most of these cell lines may be a characteristic of the transformed phenotype. Table 2 ABCA2 mRNA in Partial NCI Cell Line Panel 25 Cell Line ABCA2 Cell Line ABCA2 Melanoma Leukemic SK-MEL-28 + SR ++ 30 SK-MEL-5 ++ RPMI-8226 + UACC-257 ++ HL60-TB + UACC-62 ++ CCRF-CEM + M14 +++ MALME-3M + 35 42 WO01/21798 PCT/US00/40789 Breast LOXIMVI ++ MCF7 ++++ CNS NCI/ADR ++ 5 SF-295 ++ SF-539 + SNB-19 ++ Colon SNB-75 ++++ 10 U251 ++ HCC-2998 + HCT-116 + LUNG HCT-15 + SW ++ A549 ++ 15 NCI-H23 ++++ NCI-H460 ++ Renal NCI-H522 +++ EKVX ++++ 786-0 +++ HOP-62 + A498 +++ 20 HOP-92 ++ CAKI-1 + JK-10 ++ Prostate UO-31 + PC-3 ++ Ovarian 25 OV-CAR-3 ++ OV-CAR-5 ++ OV-CAR-8 ++ IGR-OV1 ++ 30 In summary, we have isolated the full length human ABCA2 cDNA and performed molecular and primary structure analysis on the encoded ABCA2 protein transporter. Based on the degree of amino acid identity, ABCA2 can be 35 regarded as an orthologue of mouse ABCA2 (Luciani et al., 43 WU Ul/2179 PCT/US00/40789 1994). This protein is closely related to members of the ABCAl-subfamily of transporters (ABCA1, ABCA4 and ABCA3) and more distantly related to MDR1, MRPl and CFTR. The availability of the ABCA2 cDNA and its encoded 5 protein facilitate the development of novel therapeutic agents which may be efficacious in the treatment of cancer and other disorders which result from the aberrant transport of molecules across cell membranes. 44 WV Ul/Zl/Y PCT/US00/40789 REFERENCES Allikmets, R., Gerrard, B., Hutchinson, A., Dean, M., 1996. Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the expressed 5 sequence tags database. Hum. Mol. Genet. 5, 1649-1655. Allikmets, R., Raskind, W.H., Hutchinson, A., Schueck, N.D., Dean, M., Koeller, D.M., 1999. Mutation of a putative mitochondrial iron transporter gene (ABC7) in X 10 linked sideroblastic anemia and ataxia (XLSA/A). Hum. Mol. Genet. 8, 743-749. Azarian, S.M., Travis, G.H., 1997. The photoreceptor rim protein is an ABC transporter encoded by the gene for 15 recessive Stargardt's disease (ABCR). FEBS Lett. 409, 247-252. Becq, F., Hamon, Y., Bajetto, A., Gola, M., Verrier, B., Chimini, G., 1997. ABC1, an ATP binding cassette 20 transporter required for phagocytosis of apoptotic cells, generates a regulated anion flux after expression in Xenopus laevis oocytes. J. Biol. Chem. 272, 2695-2699. Bodzioch, M., Orso, E., Klucken, J., Langmann, T., 25 Bottcher, A., Diederich, W., Drobnik, W., Barlage, S., Buchler, C., Porsch-Ozcurumez, M., Kaminski, W.E., Hahmann, H.W., Oette, K., Rothe, G., Aslanidis, C., Lackner, K.J., Schmitz, G., 1999. The gene encoding ATP binding cassette transporter 1 is mutated in Tangier 30 disease. Nat. Genet. 22, 347-351. Brooks-Wilson, A., Marcil, M., Clee, S.M., Zhang, L.H., Roomp, K., vanDam, M., Yu, L., Brewer, C., Collins, J.A., Molhuyizen, H.O., Loubser, 0., Ouelette, B.F., Fichter, 35 K., Ashbourne-Excoffon, K.J., Sensen, C.W., Scherer, S., Mott, S., Denis, M., Martindale, D., Frohlich, J., Morgan, K., Koop, B., Pimstone, S., Kastelein, J.J., Genest, J., Hayden, M.R., 1999. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein 40 deficiency. Nat. Genet. 22, 336-345. Chan, P., Simon-Chazottes, D., Mattei, M.G., Guenet, J.L., Salier, J.P., 1994. Comparative mapping of lipocalin genes in human and mouse: the four genes for 45 complement C8 gamma chain, prostaglandin-D-synthase, oncogene-24p3, and progestagen-associated endometrial protein map to HSA9 and MMU2. Genomics 23, 145-150. Collins, C.S., Gould, S.J., 1999. Identification of a 50 common PEX1 mutation in Zellweger syndrome. Hum. Mutat. 14, 45-53. 45 WO 01/21798 PCT/US00/40789 Croop, J.M., 1998. Evolutionary relationships among ABC transporters. Meth. Enzymol. 292, 101-116. Csere, P., Lill, R., Kispal, G., 1998. Identification of 5 a human mitochondrial ABC transporter, the functional orthologue of yeast Atmlp. FEBS Lett. 441, 266-270. de la Salle, H., Hanau, D., Fricker, D., Urlacher, A., Kelly, A., Salamero, J., Powis, S., Donato, L., 10 Bausinger, H., LaForet, M., 1994. Homozygous human TAP peptide transporter mutation in HLA class I deficiency. Science 2645, 237-241. Flens, M.J., Izquierdo, M.A., Scheffer, G.L., Fritz, 15 J.M., Meijer, C.J., Scheper, R.J., Zaman, G.J., 1994. Immunochemical detection of the multidrug resistance associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res. 54, 4557 4563. 20 Flower, D.R., 1996. The lipocalin protein family: structure and function. Biochem. J. 318, 1-14. Hamon, Y., Luciani, M.F., Becq, F., Verrier, B., 25 Rubartelli, A., Chimini, G., 1997. Interleukin-lbeta secretion is impaired by inhibitors of the ATP binding cassette transporter, ABC1. Blood 90, 2911-2915. Herzog, H., Baumgartner, M., Holzfeind, P., Redl, B., 30 1995. Confirmation of 9q34 as the chromosomal site of the human lipocalin LCN1 gene. Cytogenet. Cell. Genet. 69, 109-109. Hettema, E.H., Distel, B., Tabak, H.F., 1999. Import of 35 proteins into peroxisomes. Biochim. Biophys. Acta 1451, 17-34. Illing, M., Molday, L.L., Molday, R.S., 1997. The 220 kDa rim protein of retinal rod outer segments is a member 40 of the ABC transporter superfamily. J. Biol. Chem. 272, 10303-10310. Keppler, D., Leier, I., Jedlitschky, G., 1997. Transport of glutathione conjugates and glucuronides by the 45 multidrug resistance proteins MRP1 and MRP2. Biol. Chem. 378, 787-791. Kozak, M., 1991. An analysis of vertebrate mRNA sequences: intimations of translational control. J. Cell 50 Biol. 115, 887-903. 46 WO 01/21798 PCT/US00/40789 Kunzelmann, K., 1999. The cystic fibrosis transmembrane conductance regulator and its function in epithelial transport. Rev. Physiol. Biochem. Pharmacol. 137, 1-70. 5 Kusuhara, H., Suzuki, H., Naito, M., Tsuruo, T., Sugiyama, Y., 1998. Characterization of efflux transport of organic anions in a mouse brain capillary endothelial cell line. J. Pharmacol. Exper. Therapeut. 285, 1260 1265. 10 Laing, N.M., Belinsky, M.G., Kruh, G.D., Bell, D.W., Boyd, J.T., Barone, L., Testa, J.R., Tew, K.D., 1998. Amplification of the ATP-binding cassette 2 transporter gene is functionally linked with enhanced efflux of 15 estramustine in ovarian carcinoma cells. Cancer Res. 58, 1332-1337. Lewis, R.A., Shroyer, N.F., Singh, N., Allikmets, R., Hutchinson, A., Li, Y., Lupski, J.R., Leppert, M., Dean, 20 M., 1999. Genotype/phenotype analysis of a photoreceptor-specific ATP-binding cassette transporter gene, ABCR in Stargardt disease. Am. J. Hum. Genet. 64, 422-434. 25 Luciani, M.F., Chimini, G., 1996. The ATP binding cassette transporter ABC1, is required for the engulfment of corpses generated by apoptotic cell death. EMBO J. 15, 226-235. 30 Luciani, M.F., Denizot, F., Savary, S., Mattei, M.G., Chimini, G., 1994. Cloning of two novel ABC transporters mapping in human chromosome 9. Genomics 21, 150-159. Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., 35 Paull, K., Vistica, D., Hose, C.P., Vaigro-Wolff, A., 1991. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 83, 757-766. 40 Moynault, A., Luciani, M.F., Chimini, G., 1998. ABC1, the mammalian homologue of the engulfment gene ced-7, is required during phagocytosis of both necrotic and apoptotic cells. Biochem. Soc. Trans. 26, 629-635. 45 Newitt, S., Powis, S.J., 1999. Interactions formed by truncated transporter associated with antigen-processing polypeptides. Transplant Proc. 31, 1519-1521. Punzi, J.S., Duax, W.L., Strong, P., Griffin, J.F., 50 Flocco, M.M., Zacharias, D.E., Carrell, H.L., Tew, K.D., Glusker, J.P., 1992. Molecular conformation of 47 WO 01/21798 PCT/US00/40789 estramustine and two analogues. Mol. Pharmacol. 41, 569-576. Rozet, J.M., Gerber, S., Souied, E., Perrault, I., Chatelin, S., Ghazi, I., Leowski, C., Dufier, J.L., 5 Munnich, A., Kaplan, J., 1998. Spectrum of ABCR gene mutations in autosomal recessive macular dystrophies. Eur. J. Hum. Genet. 6, 291-295. Rust, Stephan, et al., 1998. Tangier disease is caused 10 by mutations in the gene encoding ATP-binding cassette transporter 1. Nature Genetics 22,352-355. Shani, N., Valle, D., 1998. Peroxisomal ABC transporters. Meth. Enzymol 292, 753-776. 15 Sharom, F.J., Liu, R., Romsicki, Y., 1998. Spectroscopic and biophysical approaches for studying the structure and function of the P-glycoprotein multidrug transporter. Biochem. Cell Biol. 76, 695-708. 20 Shroyer, N.F., Lewis, R.A., Allikmets, R., Singh, N., Dean, M., Leppert, M., Lupski, J.R., 1999. The rod photoreceptor ATP-binding cassette transporter gene, ABCR and retinal disease: from monogenic to multifactoral. 25 Vision Res. 39, 2537-2544. Smith, K.D., Kemp, S., Braiterman, L.T., Lu, J.F., Wei, H.M., Geraghty, M., Stetten, G., Bergin, J.S., 1999. X linked adrenoleukodystrophy: genes, mutations and 30 phenotypes. Neurochem. Res. 24, 521-535. Sun, H., Molday, R.S., Nathans, J., 1999. Retinal stimulates ATP hydrolysis by purified and reconstituted ABCR, the photoreceptor-specific ATP binding cassette 35 transporter responsible for Stargardt disease. J. Biol. Chem. 274, 8269-8281. Tew, K.D., Glusker, J.P., Hartley-ASP, B., Hudes, G., Speicher, L.A., 1992. Preclinical and clinical 40 perspectives on the use of estramustine as an antimitotic drug. Pharmacol. Ther. 56, 323-339. van Asperen, J., Mayer, U., van Tellingen, 0., Beijnen, J.H., 1997. The functional role of P-glycoprotein in the 45 blood-brain barrier. J. Pharm. Sci. 86, 881-884. Wang, Y., Guttoh, D.S., Androlewica, M.J., 1998. Peptide transport assay for TAP function. Meth. Enzymol. 292, 745-753. 50 Weng, J., Mata, N.L., Azarian, S.M., Tzekov, R.T., Birch, D.G., Travis, G.H., 1999. Insights into the function of 48 WO 01/21798 PCTIUS00/40789 Rim protein in photoreceptors and etiology of Stargardt's disease from the phenotype in abcr knockout mice. Cell 98, 13-23. 5 While certain of the preferred embodiments of the present invention have been described and specifically exemplified above, it is not intended that the invention be limited to such embodiments. Various modifications 10 may be made thereto without departing from the scope and spirit of the present invention, as set forth in the following claims. 49
Claims (25)
1. An isolated nucleic acid molecule having the sequence of SEQ ID NO:l, said nucleic acid molecule comprising a nucleotide sequence encoding a human ABCA2 5 transporter protein about 2436 amino acids in length, said encoded transporter protein comprising a multi-domain structure including a multiplicity of glycosylation and phosphorylation sites, a lipocalin signature motif, nucleotide binding folds having Walker A 10 and B ATP binding sites, and a plurality of membrane spanning helices.
2. The nucleic acid molecule of claim 1, which is DNA. 15
3. The DNA molecule of claim 2, which is a cDNA comprising a sequence approximately 7.3 kilobase pairs in length that encodes said human ABCA2 transporter protein. 20
4. The DNA molecule of claim 2, which is a gene comprising introns and exons, the exons of said gene specifically hybridizing with the nucleic acid of Sequence I.D. No. 1, and said exons encoding said ABCA2 25 transporter protein.
5. An isolated RNA molecule transcribed from the nucleic acid of claim 1. 30
6. The nucleic acid molecule of claim 1, wherein said sequence encodes a human ABC2 transporter protein having an amino acid sequence selected from the group consisting of Sequence I.D. No. 2 and amino acid sequences encoded by natural allelic variants of said 35 sequence. 50 WO01/21798 PCTIUS00/40789
7. The nucleic acid molecule of claim 6, which comprises Sequence I.D. No. 1.
8. An antibody immunologically specific for 5 the protein encoded by the nucleic acid of claim 1.
9. An antibody as claimed in claim 8, said antibody being monoclonal.
10 10. An antibody as claimed in claim 8, said antibody being polyclonal.
11. A plasmid comprising a nucleotide sequence having the sequence of Sequence I.D. No. 1. 15
12. A vector comprising a nucleotide sequence having the sequence of Sequence I.D. No. 1.
13. A retroviral vector comprising a 20 nucleotide sequence having the sequence of Sequence I.D. No. 1.
14. A host cell comprising a nucleic acid molecule having a sequence of Sequence I.D. No. 1. 25
15. A host cell as claimed in claim 14, wherein said host cell is selected from the group consisting of bacterial, fungal, mammalian, insect and plant cells. 30
16. A host cell as claimed in claim 14, wherein said nucleic acid is provided in a plasmid and is operably linked to mammalian regulatory elements which confer high expression and stability of mRNA transcribed 35 from said nucleic acid. 51 WO01/21798 PCT/US00/40789
17. A host cell as claimed in claim 14, wherein said nucleic acid is provided in a plasmid and is operably linked to mammalian regulatory control elements in reverse anti-sense orientation. 5
18. A host animal comprising a nucleic acid molecule having the sequence of Sequence I.D. No. 1.
19. A host animal as claimed in claim 18, 10 wherein said animal harbors a homozygous null mutation in its endogenous ABCA2 gene wherein said mutation has been introduced into said mouse or an ancestor of said mouse via homologous recombination in embryonic stem cells, and further wherein said mouse does not express a functional 15 mouse ABC2 protein.
20. The transgenic mouse of claim 18, wherein said mouse is fertile and transmits said null mutation to its offspring. 20
21. The transgenic mouse of claim 18, wherein said null mutation has been introduced into an ancestor of said mouse at an embryonic stage following microinjection of embryonic stem cells into a mouse 25 blastocyt.
22. A method for screening a test compound for inhibition of human ABCA2 mediated transport, comprising: a) providing a host cell expressing a human 30 ABCA2-encoding nucleic acid having a sequence of Sequence I.D. No. 1; b) contacting said host cell with a compound suspected of inhibiting human ABC2-mediated transporter activity; and 52 WO01/21798 PCTIUS00/40789 c) assessing inhibition of transport mediated by said compound.
23. A method as claimed in claim 22, wherein 5 inhibition of human ABCA2 mediated transport is indicated by restoration of anticancer drug sensitivity.
24. A method as claimed in claim 22, wherein said inhibition of human ABCA2 mediated transport is 10 indicated by a reduction of transporter mediated cellular efflux of anticancer agents.
25. A kit for detecting the presence of human ABCA2-encoding nucleic acids in a sample, comprising: 15 a) oligonucleotide primers specific for amplification of human ABCA2-encoding nucleic acids; b) polymerase enzyme; c) amplification buffer; and d) human ABCA2 specific DNA for use as a 20 positive control. 53
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15483999P | 1999-09-20 | 1999-09-20 | |
US60154839 | 1999-09-20 | ||
PCT/US2000/040789 WO2001021798A2 (en) | 1999-09-20 | 2000-08-31 | Nucleic acid encoding human abca transporter 2 (abca2) and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
AU1249501A true AU1249501A (en) | 2001-04-24 |
Family
ID=22553022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU12495/01A Abandoned AU1249501A (en) | 1999-09-20 | 2000-08-31 | Nucleic acid encoding human abca transporter 2 (abca2) and methods of use thereof |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1214415A4 (en) |
AU (1) | AU1249501A (en) |
CA (1) | CA2385231A1 (en) |
WO (1) | WO2001021798A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004147502A (en) * | 2000-07-26 | 2004-05-27 | Banyu Pharmaceut Co Ltd | Human and rat abca2 gene |
US20060110790A1 (en) * | 2002-05-06 | 2006-05-25 | Robert Molday | Expression system for large functional proteins |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6677100A (en) * | 1999-08-20 | 2001-03-19 | Activepass Pharmaceuticals, Inc. | Novel abc2 transporter and uses thereof |
AU2001245367A1 (en) * | 2000-02-29 | 2001-09-12 | Millennium Pharmaceuticals, Inc. | Human transporter genes and proteins encoded thereby |
JP2004147502A (en) * | 2000-07-26 | 2004-05-27 | Banyu Pharmaceut Co Ltd | Human and rat abca2 gene |
-
2000
- 2000-08-31 WO PCT/US2000/040789 patent/WO2001021798A2/en not_active Application Discontinuation
- 2000-08-31 EP EP00974068A patent/EP1214415A4/en not_active Withdrawn
- 2000-08-31 AU AU12495/01A patent/AU1249501A/en not_active Abandoned
- 2000-08-31 CA CA002385231A patent/CA2385231A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2001021798A2 (en) | 2001-03-29 |
EP1214415A4 (en) | 2003-09-17 |
EP1214415A1 (en) | 2002-06-19 |
CA2385231A1 (en) | 2001-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20040236092A1 (en) | Peptidologlycan recognition protein encoding nucleic acids and methods of use thereof | |
AU747846B2 (en) | Human potassium channel genes | |
EP1297003A2 (en) | A RECOMBINANT CELL LINE EXPRESSING GPCRx11 AS A FUNCTIONAL RECEPTOR VALIDATED BY ANGIOPEPTIN AND USEFUL FOR SCREENING OF AGONISTS AND ANTAGONISTS | |
AU732149B2 (en) | AIB1, a novel steroid receptor co-activator | |
US20100273256A1 (en) | Human Potassium Channel Genes | |
US20030149998A1 (en) | Genes encoding G-protein coupled receptors and methods of use therefor | |
US6380374B1 (en) | Human intestinal Npt2B | |
AU1249501A (en) | Nucleic acid encoding human abca transporter 2 (abca2) and methods of use thereof | |
WO1999049735A1 (en) | Mpr-related abc transporter encoding nucleic acids and methods of use thereof | |
CA2251603A1 (en) | Gene family associated with neurosensory defects | |
CA2379462A1 (en) | Human g-protein coupled receptor | |
US7312026B2 (en) | MRP-related ABC transporter encoding nucleic acids and methods of use thereof | |
AU2001272982B2 (en) | GP286 nucleic acids and polypeptides | |
US6998255B1 (en) | Human G-protein coupled receptor | |
US20030119726A1 (en) | P-glycoproteins and uses thereof | |
WO2002044212A2 (en) | Human g-protein coupled receptor and uses thereof | |
JP4224395B2 (en) | PanCAM nucleic acids and polypeptides | |
JP2004500872A (en) | GP354 nucleic acids and polypeptides | |
WO2000029578A9 (en) | Cloning and characterization of two m-rna transcription factors | |
US20040093626A1 (en) | Methods | |
JP2005503104A (en) | A novel human potassium channel β subunit | |
JP2005521424A (en) | Novel pancortin-pabroprotein interactions and methods of their use | |
US20030082555A1 (en) | Haplotypes of the icam2 gene | |
JP2004522421A (en) | Human G-protein coupled receptors and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |